内幕交易：J&J，摩根士丹利本周值得注意的名字

This week’s insider trading features sales by company insiders, including investors, executives, and board members within companies like Johnson & Johnson (NYSE:JNJ) and Morgan Stanley (NYSE:MS). The reported transactions took place between July 14 and July 18.

• John Reed, executive vice president at Johnson & Johnson, sold a stake worth $3.13 million in the company. Reed let go of 19,137 shares for $163.55 each, decreasing his ownership to 10,658 shares.
• Several Morgan Stanley executives reduced their holdings in the company this week. The most prominent of those came from CFO Sharon Yeshaya and Co-President Andrew Saperstein. Yeshaya sold 25,583 shares in the company for $139.81 apiece, totalling $3.58 million, while Saperstein offloaded 43,566 shares for $140.97 each for a total value of $6.14 million. Saperstein and Yeshaya now hold about 294,250 and 128,662 shares in the company, respectively.
• Citigroup (NYSE:C) Director Peter Henry trimmed his holding by letting go of 3,000 shares for $90.4 per share for a total worth of $271,209. Henry continues to hold 2,140 shares of the company.
• Yoram Rubanenko, executive vice president at retail chain Costco (NASDAQ:COST), sold 4,000 shares for $974.96 each for a total value of nearly $4 million. Following the transaction, Rubanenko now holds 5,774 shares in the company.
• Delta Airlines (NYSE:DAL) also saw a few of its insiders reduce their stake in the company. Among them were Alain Bellemare, EVP & president- international, and Chief External Affairs Officer Peter Carter. Bellemare let go of a total of 45,423 shares in the price range of $54.95 to $56.32 per share, totalling $2.5 million. He retains ownership of 131,731 shares in the company. Meanwhile, Carter sold 17,550 shares for $57.19 apiece, resulting in a total value of over $1 million. He now holds 191,442 shares in the company.
• Bloom Energy’s (NYSE:BE) investor SK ecoplant made a sizeable reduction in its stake by selling 10 million shares of the company for $27.6 each, for a total value of $276 million. The investor’s holding now stands at 13,491,701 shares in the company.
• On the buy side, CRISPR Therapeutics’ (NASDAQ:CRSP) Director Simeon George purchased 989,812 shares of the company for about $52.03 each, resulting in a total investment of $51.50 million. George's stake in the company has increased to 1.73 million shares.

More on Markets

• Johnson & Johnson: The Worst Is Baked In
• Dividend Roundup: Citigroup, Coca-Cola, Caterpillar, Pfizer, and more
• J&J gets FDA priority review for drug releasing system for bladder cancer